• Je něco špatně v tomto záznamu ?

Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial

H. van den Berg, M. Paulussen, G. Le Teuff, I. Judson, H. Gelderblom, U. Dirksen, B. Brennan, J. Whelan, RL. Ladenstein, P. Marec-Berard, J. Kruseova, L. Hjorth, T. Kühne, B. Brichard, K. Wheatley, A. Craft, H. Juergens, N. Gaspar, MC. Le Deley, . ,

. 2015 ; 51 (16) : 2453-64. [pub] 20150810

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010002

BACKGROUND: Based on the randomised Euro-EWING99-R1 trial, vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide (VAI) in the treatment of standard-risk Ewing sarcoma. However some heterogeneity of treatment effect by gender was observed. The current exploratory study aimed at investigating the influence of gender on treatment efficacy and acute toxicity. PATIENTS AND METHODS: Impact of gender on event-free survival (EFS), acute toxicity by course, switches between treatment arms and cumulative dose of alkylating agents was evaluated in multivariable models adjusted for age including terms to test for heterogeneity of treatment effect by gender. The analysis of the EFS was performed on the intention-to-treat population. RESULTS: EFS did not significantly differ between the 509 males and 347 females (p=0.33), but an interaction in terms of efficacy was suspected between treatment and gender (p=0.058): VAC was associated with poorer EFS than VAI in males, hazard ratio (HR) (VAC/VAI)=1.37 [95% confidence interval (CI), 0.98-1.90], contrasting with HR=0.81 [95%CI, 0.53-1.24] in females. Severe toxicity was more frequent in females, whatever the toxicity type. Thirty patients switched from VAI to VAC (9/251 males, 4%, and 21/174 females, 12%) mostly due to renal toxicity, and three from VAC to VAI (2/258 males, 0.8%, and 1/173 females, 0.6%). A reduction of alkylating agent cumulative dose >20% was more frequent in females (15% versus 9%, p=0.005), with no major difference between VAC and VAI (10% versus 13%, p=0.15). CONCLUSION: Differences of acute toxicity rate and cumulative doses of alkylating agents could not explain the marginal interaction observed in the Euro-EWING99-R1 trial data. Effects of gender-dependent polymorphism/activity of metabolic enzymes (e.g. known for CYP2B6) of ifosfamide versus cyclophosphamide should be explored. External data are required to further evaluate whether there is heterogeneity of alkylating agent effect by gender. TRIAL NUMBERS: NCT00987636 and EudraCT 2008-003658-13.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010002
003      
CZ-PrNML
005      
20160413103129.0
007      
ta
008      
160408s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejca.2015.06.123 $2 doi
024    7_
$a 10.1016/j.ejca.2015.06.123 $2 doi
035    __
$a (PubMed)26271204
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a van den Berg, Henk $u Emma Children's Hospital/Academic Medical Center, Amsterdam, The Netherlands.
245    10
$a Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial / $c H. van den Berg, M. Paulussen, G. Le Teuff, I. Judson, H. Gelderblom, U. Dirksen, B. Brennan, J. Whelan, RL. Ladenstein, P. Marec-Berard, J. Kruseova, L. Hjorth, T. Kühne, B. Brichard, K. Wheatley, A. Craft, H. Juergens, N. Gaspar, MC. Le Deley, . ,
520    9_
$a BACKGROUND: Based on the randomised Euro-EWING99-R1 trial, vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide (VAI) in the treatment of standard-risk Ewing sarcoma. However some heterogeneity of treatment effect by gender was observed. The current exploratory study aimed at investigating the influence of gender on treatment efficacy and acute toxicity. PATIENTS AND METHODS: Impact of gender on event-free survival (EFS), acute toxicity by course, switches between treatment arms and cumulative dose of alkylating agents was evaluated in multivariable models adjusted for age including terms to test for heterogeneity of treatment effect by gender. The analysis of the EFS was performed on the intention-to-treat population. RESULTS: EFS did not significantly differ between the 509 males and 347 females (p=0.33), but an interaction in terms of efficacy was suspected between treatment and gender (p=0.058): VAC was associated with poorer EFS than VAI in males, hazard ratio (HR) (VAC/VAI)=1.37 [95% confidence interval (CI), 0.98-1.90], contrasting with HR=0.81 [95%CI, 0.53-1.24] in females. Severe toxicity was more frequent in females, whatever the toxicity type. Thirty patients switched from VAI to VAC (9/251 males, 4%, and 21/174 females, 12%) mostly due to renal toxicity, and three from VAC to VAI (2/258 males, 0.8%, and 1/173 females, 0.6%). A reduction of alkylating agent cumulative dose >20% was more frequent in females (15% versus 9%, p=0.005), with no major difference between VAC and VAI (10% versus 13%, p=0.15). CONCLUSION: Differences of acute toxicity rate and cumulative doses of alkylating agents could not explain the marginal interaction observed in the Euro-EWING99-R1 trial data. Effects of gender-dependent polymorphism/activity of metabolic enzymes (e.g. known for CYP2B6) of ifosfamide versus cyclophosphamide should be explored. External data are required to further evaluate whether there is heterogeneity of alkylating agent effect by gender. TRIAL NUMBERS: NCT00987636 and EudraCT 2008-003658-13.
650    _2
$a mladiství $7 D000293
650    _2
$a alkylační protinádorové látky $x aplikace a dávkování $x škodlivé účinky $7 D018906
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $7 D000971
650    _2
$a nádory kostí $x farmakoterapie $x patologie $7 D001859
650    _2
$a cyklofosfamid $x aplikace a dávkování $7 D003520
650    _2
$a progrese nemoci $7 D018450
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a doxorubicin $x aplikace a dávkování $7 D004317
650    _2
$a náhrada léků $7 D057915
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a disparity zdravotního stavu $7 D054624
650    _2
$a lidé $7 D006801
650    _2
$a ifosfamid $x aplikace a dávkování $7 D007069
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a rizikové faktory $7 D012307
650    _2
$a Ewingův sarkom $x farmakoterapie $x patologie $7 D012512
650    _2
$a sexuální faktory $7 D012737
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vinkristin $x aplikace a dávkování $7 D014750
651    _2
$a Evropa $7 D005060
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Paulussen, Michael $u Vestische Kinder-und Jugendklinik Datteln, Witten/Herdecke University, Datteln, Germany.
700    1_
$a Le Teuff, Gwénaël $u Institute Gustave Roussy, Villejuif, France.
700    1_
$a Judson, Ian $u The Royal Marsden NHS Foundation Trust, London, United Kingdom.
700    1_
$a Gelderblom, Hans $u Leiden University Medical Center, Leiden, The Netherlands.
700    1_
$a Dirksen, Uta $u Department of Paediatric Hematology and Oncology, University Hospital, Muenster, Germany.
700    1_
$a Brennan, Bernadette $u Royal Manchester Children's Hospital, Manchester, United Kingdom.
700    1_
$a Whelan, Jeremy $u University College Hospital, London, United Kingdom.
700    1_
$a Ladenstein, Ruth Lydia $u St. Anna Children's Hospital and Research Institute, Vienna, Austria.
700    1_
$a Marec-Berard, Perrine $u Institut d'Hématologie et d'Oncologie Pédiatrie, Lyon, France.
700    1_
$a Kruseova, Jarmila $u Department of Paediatric Haematology and Oncology, Charles University, Motol Hospital, Prague, Czech Republic.
700    1_
$a Hjorth, Lars $u Skåne University Hospital, Lund University, Lund, Sweden.
700    1_
$a Kühne, Thomas $u University Children's Hospital Basel, Basel, Switzerland.
700    1_
$a Brichard, Benedicte $u Cliniques Universitaires Saint Luc, Brussels, Belgium.
700    1_
$a Wheatley, Keith $u Cancer Research UK, Cancer Trials Unit, University of Birmingham, Birmingham.
700    1_
$a Craft, Alan $u United Kingdom Sir James Spence Institute, Newcastle upon Tyne, United Kingdom.
700    1_
$a Juergens, Heribert $u Department of Paediatric Hematology and Oncology, University Hospital, Muenster, Germany.
700    1_
$a Gaspar, Nathalie $u Institute Gustave Roussy, Villejuif, France.
700    1_
$a Le Deley, Marie-Cécile $u Institute Gustave Roussy, Villejuif, France; Paris-Sud University, Le Kremlin-Bicêtre, France.
700    1_
$a ,
773    0_
$w MED00009626 $t European journal of cancer (Oxford, England 1990) $x 1879-0852 $g Roč. 51, č. 16 (2015), s. 2453-64
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26271204 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160413103213 $b ABA008
999    __
$a ok $b bmc $g 1113431 $s 934370
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 51 $c 16 $d 2453-64 $e 20150810 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Možnosti archivace